Biofrontera Inc. (NASDAQ:BFRI) Sees Large Decline in Short Interest

Biofrontera Inc. (NASDAQ:BFRI) saw a significant drop in short interest during the month of September. As of September 30th, there was short interest totaling 146,851 shares, a drop of 68.4% from the September 15th total of 464,825 shares. Based on an average trading volume of 403,096 shares, the days-to-cover ratio is presently 0.4 days. Currently, 1.1% of the company’s shares are short sold.

Analyst Ratings Changes

Several brokerages recently commented on BFRI. Wall Street Zen cut Biofrontera from a “buy” rating to a “hold” rating in a report on Sunday, September 20th. Zacks Research upgraded shares of Biofrontera from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Biofrontera in a research report on Tuesday. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Biofrontera presently has an average rating of “Hold”.

Biofrontera Trading Down 3.6%

BFRI traded down $0.03 during trading on Wednesday, reaching $0.86. 24,427 shares of the stock traded hands, compared to its average volume of 413,926. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $12.77 million, a PE ratio of -1.91 and a beta of 0.86. The stock’s 50-day moving average is $1.28 and its 200 day moving average is $1.11. Biofrontera has a 12 month low of $0.55 and a 12 month high of $1.66.

Biofrontera (NASDAQ:BFRI) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. Biofrontera had a negative return on equity of 145.81% and a negative net margin of 13.78%. The firm had revenue of $12.00 million during the quarter, compared to the consensus estimate of $9.50 million. Equities analysts anticipate that Biofrontera will post -0.60 earnings per share for the current year.

Biofrontera Company Profile

Biofrontera Inc (NASDAQ:BFRI) is a specialty pharmaceutical company focused on developing and commercializing dermatology products in the United States. The company’s activities center on treatments for actinic keratosis, a common precancerous skin condition caused by sun exposure.

Biofrontera’s principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, a prescription treatment used in combination with photodynamic therapy to treat mild-to-moderate actinic keratoses on the face and scalp.